Biomedical Research
Online ISSN : 1880-313X
Print ISSN : 0388-6107
ISSN-L : 0388-6107
Full Papers
Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients
Yuji SHIMODATakeshi NAGASHIMAKenichi URAKAMIFukumi KAMADASou NAKATANIMaki MIZUGUCHIMasakuni SERIZAWAKeiichi HATAKEYAMAKeiichi OHSHIMATohru MOCHIZUKISumiko OHNAMIShumpei OHNAMITakeshi KAWAKAMIKentaro YAMAZAKIHaruyasu MURAKAMIHirotsugu KENMOTSUAkio SHIOMIYasuto AKIYAMAKen YAMAGUCHI
Author information
JOURNAL FREE ACCESS

2022 Volume 43 Issue 4 Pages 115-126

Details
Abstract

Next-generation sequencing (NGS) is an integral part of precision medicine, and its power for detecting comprehensive genetic alterations may contribute to treatment decisions for patients with advanced, recurrent, or metastatic cancer. An NGS oncology panel developed in the U.S. and Europe, which targets cancer-related genes, has been approved in Japan, and testing is becoming more widespread in clinical oncology practice. However, these panels are based on cancer-related genes selected from cancer databases of Westerners. We aimed to develop an onco-panel for Japanese. We designed two High-tech Omics-based Patient Evaluation (HOPE) onco-panels: HOPE onco-panel Solid for solid tumors and HOPE onco-panel Liquid for liquid biopsy. These were based on genomic information of 5,143 cancer cases in the Japanese Cancer Genome Atlas (JCGA), a database of Japanese cancer cases. Their performance was confirmed using clinical data.

Content from these authors
© 2022 Biomedical Research Press
Previous article Next article
feedback
Top